Here All Year: What did you learn about MBC?
Revisit highlights and test your knowledge with our short quiz.
Launched in October 2020, our Here All Year awareness campaign was built around a simple truth: while October is breast cancer awareness month, people with metastatic breast cancer live with their diagnosis year-round – and public education and advocacy must keep pace.
Here All Year was created to bridge that gap by exploring a new topic around metastatic breast cancer each month. By sharing everything from myth busters and personal stories to new research and strategies for improving outcomes, the campaign both raised awareness and shared important facts and resources with patients, caregivers and the public.
Revisit the highlights of our year-long campaign, then take our short quiz to test your knowledge. Bonus: help make a difference for MBC by sharing with a friend!
Here All Year was conceived by Alliance member and former Awareness Task Force Co-Chair Katherine O’Brien, who passed away in June 2021. We are forever grateful for her keen wit, insight and tireless advocacy on behalf of others also living with MBC.
Click here to watch a short video honoring Katherine and her contributions.
We are Here all Year.
How much do you know about metastatic breast cancer?
Take our short quiz to test your knowledge about metastatic breast cancer (MBC), based on facts from our Here All Year multi-media library.
Results
#1. How many people in the United States are living with MBC?
The correct answer is: We don’t know
October: Metastatic Breast Cancer Awareness Month
We don’t know the exact number, since the SEER registry currently only records cases of de novo metastatic breast cancer (disease that is already Stage IV at the initial diagnosis). An effort to track metastatic cases arising from recurrence of an early-stage cancer is now in a pilot phase.
#2. What part of the body is rarely included in initial scans for metastasis?
The correct answer is: Brain
NOVEMBER: BREAST CANCER BRAIN METASTASIS AWARENESS
While all of these are common sites of metastatic breast cancer, most MBC patients do not receive a brain scan unless they report numbness or headaches. The incidence of brain metastasis is expected to grow as new therapies help people with MBC to live longer.
#3. Which of the following are subtypes of metastatic breast cancer?
The correct answer is: All of the above
JANUARY: MOLECULAR SUBTYPES OF MBC AWARENESS
Testing for cancer subtypes helps your doctor decide which treatment options are most appropriate for you. If a cancer is hormone receptor positive (HR ), a patient can be either estrogen receptor-positive (ER ), progesterone receptor-positive (PR ) or both. Other molecular subtypes include HER2 (human epidermal growth factor receptor 2), TNBC (triple negative: ER-, PR- & HER2-), and Triple Positive (ER /PR /HER2 ).
#4. You don’t have to have a lump to have breast cancer.
The correct answer is: True
APRIL: INFLAMMATORY BREAST CANCER AWARENESS
Inflammatory breast cancer, a rare and very aggressive disease, can be difficult to diagnose since there is often no lump that can be felt during a physical exam or seen in a screening mammogram. Symptoms can include pain, swelling, a rapid increase in breast size, redness and “orange peel” or dimpling of the skin. (Lobular breast cancer can also present without a lump.)
#5. Male patients are not eligible for breast cancer clinical trials.
The correct answer is: False
DECEMBER: METASTATIC BREAST CANCER IN MEN AWARENESS
Historically, men have been excluded from clinical trials of breast cancer drugs, which has resulted in limited FDA-approved treatment options for males with breast cancer. The FDA now recommends that clinical trials of breast cancer drugs allow for the inclusion of both males and females. Please note that currently, there is no data outside of the terms “male” and “female”. We hope for future studies that are inclusive of all gender identities.
#6. Which of these activities can be part of Integrative Oncology Care?
The correct answer is: All of the above
SEPTEMBER: INTEGRATIVE ONCOLOGY CARE
Integrative care brings together the components of mind, body and soul to improve quality of life, even while going through treatment – which for people living with MBC, is most likely the rest of their life. Integrative oncology practices and cancer support organizations can connect those with MBC to evidence-informed resources for supporting physical, mental and emotional wellbeing to make every day the best that it can be.
#7. The mortality rate of MBC is significantly higher among young Black women than young white women.
The correct answer is: True
FEBRUARY: EDUCATING AND RAISING AWARENESS OF MBC IN BLACK WOMEN
According to 2017 CDC data, Black women are more likely to die of breast cancer than any other demographic, due to a combination of factors including systemic bias and less accessibility to affordable preventative care and treatment. Black women are also more likely to have aggressive forms of cancer.
#8. What percentage of adult cancer patients participate in clinical trials?
The correct answer is: Less than 5%
MARCH: CLINICAL TRIALS 101
Clinical trials offer multiple benefits, from allowing patients to try new treatment options to advancing the approval of effective new drugs. Yet fewer than 5% of adult cancer patients participate in this critical step in the research process. Barriers may include lack of access to good information, financial burden, overly restrictive exclusion criteria, or lack of access to study sites.
#9. What percentage of breast cancers are hereditary?
The correct answer is: 5-10%
MAY: GENETIC AND BIOMARKER TESTING AWARENESS
An estimated 5-10% of all breast cancers are hereditary; and a significant portion of MBC patients have harmful inherited genetic mutations that increase cancer risk. Hereditary cancers tend to occur at younger ages and are often more aggressive than non-hereditary cancers. According to National Comprehensive Cancer Network guidelines, women of any age with metastatic breast cancer may benefit from genetic counseling and testing to tailor their treatment.
#10. Who can act as a caregiver for a person living with cancer?
The correct answer is: All of the above
JUNE: CAREGIVERS AND MBC
A caregiver is normally defined as the person who most often helps the person with cancer and is not paid to do so. Family, close friends, co-workers, or neighbors may fill this role. Good, reliable caregiver support is crucial to the physical and emotional well-being of people with cancer. Cancer support organizations offer many resources that can be of help to caregivers in fulfilling this demanding, important job.
#11. Where can invasive lobular carcinoma metastasize?
The correct answer is: All of the above
JULY: METASTATIC LOBULAR BREAST CANCER AWARENESS
In invasive lobular carcinoma (ILC), cells grow in a single file and do not always form a lump or a mass. This can make it harder to diagnose. ILC metastases can spread to unusual sites such as the gastrointestinal tract (i.e., stomach, small intestine, colon), gynecological organs (i.e., ovaries, uterus), the leptomeninges (lining of the brain and spinal cord), the orbital canal (tissues behind the eye), and more. It is important for patients with lobular breast cancer to recognize and report to their oncologist any possible symptoms referring to these unusual sites of metastases.
#12. Which of the following are ways to care for the “whole” you after an MBC diagnosis?
The correct answer is: All of the above
AUGUST: NEWLY DIAGNOSED WITH MBC
Metastatic breast cancer is life-changing, and getting a diagnosis can feel like an emotional roller coaster. It is important to have both supportive connections and personal coping strategies to maintain quality of life. Working with a healthcare team or a professional therapist can help manage anxiety and depression. Support organizations also exist to connect people with MBC to a community that understands what they are experiencing, and to provide information and resources for navigating changes in daily life, managing stress and understanding treatment options.
